Tags

Type your tag names separated by a space and hit enter

New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies.
Spectrochim Acta A Mol Biomol Spectrosc. 2020 Feb 15; 227:117534.SA

Abstract

Two novel ruthenium(II) polypyridyl complexes, namely, [Ru(dmp)2(CAPIP)](ClO4)2 (Ru(II)-1) and [Ru(dmp)2(CFPIP)](ClO4)2 (Ru(II)-2), which respectively contain (E)-2-(2-(furan-2-yl)vinyl)-1H-imidazo[4,5-f][1,10]phen-anthroline (CAPIP) and (E)-2-(4-fluorostyryl)-1H-imidazo[4,5-f][1,10]phenanthroline. (CFPIP), were first designed and characterized (dmp = 2,9-dimethyl-1,10-phenanthroline). DNA binding experiments indicated that Ru(II) complexes interact with CT DNA through intercalative mode. In addition, the complexes Ru(II)-1 and Ru(II)-2, showed remarkable cell cytotoxicity, giving the respective IC50 values of 4.1 ± 1.4 μM and 6.1 ± 1.4 μM on the A549 cancer cells. These values indicated higher activity than CAPIP, CFPIP, cisplatin (8.2 ± 1.4 μM) and other corresponding Ru(II) polypyridyl complexes. Furthermore, the Ru(II) complexes could arrive the cytoplasm through the cell membrane and accumulate in the mitochondria. Significantly, complexes Ru(II)-1 and Ru(II)-2 induced A549 cells apoptosis was mediated by increase of ROS levels and dysfunction of mitochondria, and resulted in cell cycle arrest and increased anti-migration activity on A549 cells. Overall, these results indicated that complexes Ru(II)-1 and Ru(II)-2 could be suitable candidates for further investigation as a chemotherapeutic agent in the treatment of tumors.

Authors+Show Affiliations

Guangxi Key Laboratory of Electrochemical and Magnetochemical Function Materials, College of Chemistry and Bioengineering, Guilin University of Technology, Guilin, 541004, China. Electronic address: jianggb@glut.edu.cn.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31685424

Citation

Jiang, Guang-Bin, et al. "New Ruthenium Polypyridyl Complexes Functionalized With Fluorine Atom or Furan: Synthesis, DNA-binding, Cytotoxicity and Antitumor Mechanism Studies." Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, vol. 227, 2020, p. 117534.
Jiang GB, Zhang WY, He M, et al. New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies. Spectrochim Acta A Mol Biomol Spectrosc. 2020;227:117534.
Jiang, G. B., Zhang, W. Y., He, M., Gu, Y. Y., Bai, L., Wang, Y. J., Yi, Q. Y., & Du, F. (2020). New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 227, 117534. https://doi.org/10.1016/j.saa.2019.117534
Jiang GB, et al. New Ruthenium Polypyridyl Complexes Functionalized With Fluorine Atom or Furan: Synthesis, DNA-binding, Cytotoxicity and Antitumor Mechanism Studies. Spectrochim Acta A Mol Biomol Spectrosc. 2020 Feb 15;227:117534. PubMed PMID: 31685424.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies. AU - Jiang,Guang-Bin, AU - Zhang,Wen-Yao, AU - He,Miao, AU - Gu,Yi-Ying, AU - Bai,Lan, AU - Wang,Yang-Jie, AU - Yi,Qiao-Yan, AU - Du,Fan, Y1 - 2019/10/25/ PY - 2019/07/24/received PY - 2019/08/27/revised PY - 2019/09/13/accepted PY - 2019/11/7/pubmed PY - 2019/11/7/medline PY - 2019/11/6/entrez KW - Antitumor KW - Cell cycle arrest KW - DNA binding KW - Reactive oxygen species KW - Ru(II) polypyridyl complex SP - 117534 EP - 117534 JF - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy JO - Spectrochim Acta A Mol Biomol Spectrosc VL - 227 N2 - Two novel ruthenium(II) polypyridyl complexes, namely, [Ru(dmp)2(CAPIP)](ClO4)2 (Ru(II)-1) and [Ru(dmp)2(CFPIP)](ClO4)2 (Ru(II)-2), which respectively contain (E)-2-(2-(furan-2-yl)vinyl)-1H-imidazo[4,5-f][1,10]phen-anthroline (CAPIP) and (E)-2-(4-fluorostyryl)-1H-imidazo[4,5-f][1,10]phenanthroline. (CFPIP), were first designed and characterized (dmp = 2,9-dimethyl-1,10-phenanthroline). DNA binding experiments indicated that Ru(II) complexes interact with CT DNA through intercalative mode. In addition, the complexes Ru(II)-1 and Ru(II)-2, showed remarkable cell cytotoxicity, giving the respective IC50 values of 4.1 ± 1.4 μM and 6.1 ± 1.4 μM on the A549 cancer cells. These values indicated higher activity than CAPIP, CFPIP, cisplatin (8.2 ± 1.4 μM) and other corresponding Ru(II) polypyridyl complexes. Furthermore, the Ru(II) complexes could arrive the cytoplasm through the cell membrane and accumulate in the mitochondria. Significantly, complexes Ru(II)-1 and Ru(II)-2 induced A549 cells apoptosis was mediated by increase of ROS levels and dysfunction of mitochondria, and resulted in cell cycle arrest and increased anti-migration activity on A549 cells. Overall, these results indicated that complexes Ru(II)-1 and Ru(II)-2 could be suitable candidates for further investigation as a chemotherapeutic agent in the treatment of tumors. SN - 1873-3557 UR - https://www.unboundmedicine.com/medline/citation/31685424/New_ruthenium_polypyridyl_complexes_functionalized_with_fluorine_atom_or_furan:_Synthesis_DNA_binding_cytotoxicity_and_antitumor_mechanism_studies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-1425(19)30924-2 DB - PRIME DP - Unbound Medicine ER -